Biogen, EU
We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The ...
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback